3-(3-(1-(4-chlorophenyl)cyclopropyl)-[1,2,4]triazolo[4,3-a]pyridin-8-yl)-3-methylbutan-1-ol | 1140898-24-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氮杂环庚烷
• 英文名称: 3-(3-(1-(4-chlorophenyl)cyclopropyl)-[1,2,4]triazolo[4,3-a]pyridin-8-yl)-3-methylbutan-1-ol
• 英文别名: 3-[3-[1-(4-Chlorophenyl)cyclopropyl]-[1,2,4]triazolo[4,3-a]pyridin-8-yl]-3-methylbutan-1-ol
• CAS: 1140898-24-3
• 化学式: C₂₀H₂₂ClN₃O
• 分子量: 355.867
• InChiKey: AOCAWQPFJXXOHX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.9
• 重原子数：
  25
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  50.4
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• TRIAZOLOPYRIDINE 11-BETA HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORS
  申请人：Li Jun

  公开号：US20090093516A1

  公开（公告）日：2009-04-09

  Novel compounds are provided which are 11 -beta-hydroxysteroid dehydrogenase type I inhibitors. 11-beta-hydroxysteroid dehydrogenase type I inhibitors are useful in treating, preventing, or slowing the progression of diseases requiring 11-beta-hydroxysteroid dehydrogenase type I inhibitor therapy. These novel compounds of formula I: or stereoisomers or pharmaceutically acceptable salts thereof, wherein G, Q, X, Y, R 3 , R 3a , and R 3b are defined herein.

  提供了一种新的化合物，它们是11-β-羟基类固醇脱氢酶I型抑制剂。11-β-羟基类固醇脱氢酶I型抑制剂在治疗、预防或减缓需要11-β-羟基类固醇脱氢酶I型抑制剂治疗的疾病的进展方面是有用的。这些具有式I的新化合物： 或其立体异构体或药用可接受的盐，其中G、Q、X、Y、R3、R3a和R3b在此处被定义。
• US8119658B2
  申请人：——

  公开号：US8119658B2

  公开（公告）日：2012-02-21
• US8541444B2
  申请人：——

  公开号：US8541444B2

  公开（公告）日：2013-09-24
• [EN] TRIAZOLOPYRIDINE 11-BETA HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORS<br/>[FR] INHIBITEURS DE TRIAZOLOPYRIDINE 11-BÊTA HYDROXYSTÉROÏDE DÉHYDROGÉNASE DE TYPE I
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2009045753A1

  公开（公告）日：2009-04-09

  Novel compounds are provided which are 11-beta-hydroxysteroid dehydrogenase type I inhibitors. 11-beta-hydroxysteroid dehydrogenase type I inhibitors are useful in treating, preventing, or slowing the progression of diseases requiring 11-beta-hydroxysteroid dehydrogenase type I inhibitor therapy. These novel compounds of formula I: or stereoisomers or pharmaceutically acceptable salts thereof, wherein G, Q, X, Y, R3, R3a, and R3b are defined herein.